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Condensation:  Recent data from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) 1 
Follow Up Study demonstrate clear long term adverse maternal and offspring effects from mild 2 
hyperglycemia in pregnancy 3 
Short title: Gestational diabetes in 2019  4 
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Abstract 1 
Gestational diabetes mellitus is the most frequent medical complication of pregnancy, affecting 5-6% 2 
of women in the USA using the currently predominant Carpenter Coustan criteria, which still represent 3 
the preferred approach of the American College of Obstetricians and Gynecologists.  Alternative 4 
criteria proposed by the International Association of Diabetes in Pregnancy Study Groups (IADPSG) 5 
would likely increase gestational diabetes (GDM) prevalence to 15 – 20%, due both to a one step 6 
testing policy and the requirement for only one elevated glucose value for diagnosis.  Increasing GDM 7 
prevalence relates to older maternal age and the increasing prevalence of overweight and obesity. 8 
This increased GDM prevalence is consistent with 29.3% prevalence of prediabetes and 4.5% 9 
prevalence of known diabetes outside pregnancy in US adults between 20 – 44 years of age.  10 
Gestational diabetes by the IADPSG criteria is associated with almost twice the risk of large for 11 
gestational age babies, increased fetal adiposity, neonatal hyperinsulinemia and pre-eclampsia and a 12 
50% higher risk of preterm delivery and shoulder dystocia. The recent publication of the 13 
Hyperglycemia and Adverse Pregnancy Outcome (HAPO)  Follow Up Study provides further evidence 14 
regarding the influence of gestational diabetes on long term maternal and infant health.  This study 15 
clearly demonstrates that hyperglycemia in pregnancy, untreated and identified post hoc by IADPSG 16 
criteria, carries a 41.5% risk of maternal prediabetes (Odds ratio 3.72; 95% CI 3.09 – 4.47) and 10.7% 17 
risk of type 2 diabetes (Odds ratio 7.63; 95% CI 5.33 – 10.95) after 11.4 years follow up.  Gestational 18 
diabetes was also associated with higher rates of childhood overweight and obesity (prevalence 19 
39.3% with maternal gestational diabetes; Odds ratio 1.5; 95% CI 1.56 – 2.44).  This paper places 20 
these findings in the context of other recent studies demonstrating that interventions including lifestyle 21 
measures and / or metformin offer a >50% reduction in the risk of women with GDM developing overt 22 
diabetes after their index GDM pregnancy.   Although prevention of obesity and prediabetes in 23 
offspring by pregnancy treatment of gestational diabetes has not been demonstrated to date, we 24 
argue that the immediate pregnancy benefits and opportunities for long term improvements in 25 
maternal health justify a reevaluation of the current ambivalent approach taken by the American 26 
College of Obstetricians and Gynecologists to gestational diabetes diagnosis.   These currently allow 27 
for a choice of alternative criteria.  The Carpenter – Coustan or National Diabetes Data Group criteria, 28 
listed as preferred criteria by ACOG, markedly limit the frequency of gestational diabetes in 29 
comparison to IADPSG criteria and limit the opportunity for immediate and long term follow up and 30 
treatment.  We consider that new information from the Hyperglycemia and Pregnancy Outcome 31 
Follow Up Study and other recent publications on long term maternal and offspring risk provides 32 
compelling arguments for a more comprehensive approach to the promotion of maternal and infant 33 
health through all the life cycle. 34 
 35 
Keywords:  pregnancy, diagnostic criteria, HAPO, follow up, type 2 diabetes, impaired fasting glucose, 36 
impaired glucose tolerance, hyperglycemia in pregnancy, health economic studies, one step testing, 37 
two step testing, FIGO, non – communicable disorder  38 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 4 
The relationship between hyperglycemia in pregnancy and adverse pregnancy outcome is 1 
continuous, not dichotomous  2 
 3 
Data from a blinded multinational cohort of 23,316 women and their singleton offspring the HAPO 4 
study, 1, provided clear evidence of the independent and continuous linear relationship between 5 
nondiabetic hyperglycemia and a range of pregnancy complications and neonatal outcomes.  The  6 
primary outcomes were large for gestational age (LGA) infants (birthweight > 90th centile), primary 7 
cesarean delivery, clinical neonatal hypoglycemia (symptoms or treatment with a glucose infusion or a 8 
local laboratory report of a glucose value of 30.6 mg /dL or less in the first 24 hours after birth or 45.0 9 
mg / dL or less after the first 24 hours) and fetal hyperinsulinemia (cord c peptide > 90th centile for the 10 
HAPO cohort).  The major secondary outcomes included preterm birth, shoulder dystocia / birth injury, 11 
admission to newborn intensive care unit, hyperbilirubinemia and preeclampsia.  Figure 1 provides a 12 
graphical depiction of the risk of the HAPO study primary outcomes across increasing categories of 13 
fasting glucose in the HAPO study.  Similar trends are seen when considering one hour or two hour 14 
oral glucose tolerance test (OGTT) glucose results 1. 15 
 16 
New diagnostic criteria for gestational diabetes 17 
The results of the HAPO study led to an international consensus process sponsored by the 18 
International Association of Diabetes in Pregnancy Study Groups (IADPSG) to redefine gestational 19 
diabetes (GDM), leading to recommendations for a one step approach to diagnosis and classification 20 
of hyperglycemia in pregnancy according to thresholds corresponding to adjusted odds ratios (aORs) 21 
of 1.75 compared to the mean for  three neonatal outcomes -  LGA, excess adiposity (% body fat > 22 
90th percentile) and neonatal hyperinsulinemia 2.   This contrasts with the traditional US definition of 23 
GDM based on the risk of maternal progression to diabetes post-partum 3, using data derived from a 24 
small cohort of 752 women recruited by O’Sullivan et al in Boston in the late 1950s, later re-analyzed 25 
to provide the basis for current “two step” testing 4.  Strikingly, O’Sullivan reported that “16.2% were 26 
20% or more above their ideal body weight”,  compared to the recent prevalence of obesity in US 27 
women aged 20 – 39 years of 37% 5.   28 
The IADPSG approach has been endorsed by the World Health Organization (WHO) 6, 7 and the 29 
International Federation of Gynecology and Obstetrics (FIGO) 8, but has not been widely accepted  in 30 
North America and varying opinions have been expressed in the pages of this journal 9, 10.  In the 31 
USA, the American College of Obstetricians and Gynecologists (ACOG) 11 has continued to favor the 32 
traditional two step approach. In Canada the Canadian Diabetes Association 12  has favored higher 33 
diagnostic thresholds, primarily based on concerns regarding increased frequency of GDM diagnosis 34 
with the IADPSG approach.  Table 1 summarizes both immediate and longer-term outcomes in the 35 
HAPO study, according to the presence or absence of gestational diabetes by IADPSG criteria. 36 
Ten to fourteen year follow up of infants and mothers enrolled in the HAPO study 37 
The recent publication of the HAPO Follow up Study (FUS) 13 (see Table 1), provides a long term 38 
view of the maternal and offspring consequences of pregnancy hyperglycemia; thus offering another 39 
opportunity to review issues relating to GDM informed by 10 – 14 year follow up of both mothers and 40 
infants from the original study and to place these in the context of other research published over the 41 
last decade.  HAPO FUS included 4747 mothers and 4834 infants from the original study, drawn from 42 
10 of the 15 initial HAPO Field Centers.  Median time post-birth at follow up was 11.4 years. 43 
Overall, 52.2% of mothers with GDM based on IADPSG criteria, who were blinded and untreated  44 
during their index pregnancy developed prediabetes (composite of impaired glucose tolerance (IGT); 45 
impaired fasting glucose (IFG)) or Type 2 diabetes (T2D) at follow up as compared to 20.1% of those 46 
without IADPSG GDM.  The fully adjusted odds ratio (including adjustment for maternal BMI at follow 47 
up) for impaired glucose metabolism was 3.44 (95% CI 2.85 – 4.14) and for T2D 5.44 (95%CI 3.68 – 48 
8.08).  Thus, a diagnosis of GDM based on IADPSG criteria at the index pregnancy carried a very 49 
strong risk for future metabolic abnormalities. 50 
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IADPSG GDM in the mother was also associated with offspring overweight or obesity (39.5 vs. 1 
28.6%), with a stronger trend for obesity alone (19.1 vs. 9.9%).  The combined outcome of offspring 2 
overweight and obesity just failed to reach statistical significance after adjustment for field center, 3 
pubertal status and maternal variables at the OGTT visit:- age, height, family history of diabetes, 4 
mean arterial pressure, parity, smoking status, alcohol consumption, gestational age and BMI  (OR 5 
1.21; 95% CI 1.00 – 1.46) but obesity remained significant (OR 1.58; 95% CI 1.24 – 2.01) 6 
The HAPO FUS also published additional analyses comparing long term outcomes in women and 7 
their offspring classified post hoc as having gestational diabetes by IADPSG or the more stringent 8 
Carpenter -Coustan criteria commonly used in the USA 14.  As expected due to the more marked 9 
maternal hyperglycemia identified by the Carpenter – Coustan criteria, the frequency of maternal 10 
impaired glucose metabolism following GDM was 68.4% and of T2DM 20.0% when Carpenter - 11 
Coustan criteria were used. Although not presented in the recent publication, the relationships 12 
between maternal glycemia during pregnancy and later maternal and child outcomes were 13 
continuous, as reported for immediate pregnancy outcomes in earlier publications.  14 
Gestational diabetes  frequency and impaired glucose metabolism outside pregnancy 15 
The most frequent concern among those opposed to the IADPSG diagnostic criteria is the marked 16 
increase in GDM frequency.  In the USA, a 2013 National Institutes of Health (NIH) panel estimated 17 
that GDM frequency would rise from 5 – 6% using Carpenter - Coustan criteria to 15 – 20% with the 18 
IADPSG approach  15.  Indeed,  in the US based HAPO field centers, IADPSG GDM frequency 19 
ranged from 17.3 % in Chicago IL to 25.5% in Bellflower CA 16.  In this context it is important to note 20 
that the US population data from the most recent National Health and Nutrition Examination 21 
(NHANES) surveys demonstrate that 4.5% of US adults age 20 – 44 years have overt diabetes 17 and 22 
a further 29.3% prediabetes (HbA1c 5.7 – 6.4 and / or fasting glucose 100 – 126 mg /dL and / or 2 23 
hour OGTT glucose 140 – 199 mg / dL)  18.  Even at age 12 – 19 years, diabetes affects 0.6% and 24 
prediabetes 13.2% of US females 19.   Thus, if women of reproductive age were routinely tested prior 25 
to pregnancy, over 30% would be found to have prediabetes or diabetes.  The fact that many cases of 26 
GDM represent preexisting prediabetes or diabetes has been recognized for many years 20, but is not 27 
always adequately considered when discussing likely GDM prevalence.    More recent data from the 28 
US based CARDIA study 21 which recruited women before pregnancy (Age 18 – 30 years) and 29 
followed them longitudinally, clearly demonstrate that abnormalities in glucose and lipid metabolism 30 
are detectable many years before a GDM diagnosis is made. 31 
Given that pregnancy is a potent "metabolic stressor" due to increased insulin resistance and the 32 
need for beta cell adaptation 22-24, why should there be surprise that up to 25% US women might be 33 
diagnosed with GDM?  Refusal to accept GDM as a very common condition reflects a denial of the 34 
facts and a refusal to address the problems posed by concurrent epidemics of diabetes and obesity 35 
affecting women of child bearing age. Besides the immediate perinatal outcomes, hyperglycemia in 36 
pregnancy is a highly reliable marker of future type 2 diabetes; relative risk (RR) 7.43 (95% CI 4.79–37 
11.51). 25; cardio metabolic disorders (RR 1.66, 95% CI 1.30-2.13) and renal disease (Odds ratio 38 
(OR)  2.3, 95% CI 1.4-3.7) 26-28.    Other pregnancy complications including the development of 39 
gestational hypertension 29, early term delivery 30and occurrence of placental complications 31 may 40 
also help to identify future cardiometabolic risks. In women with prior GDM, post-partum lifestyle 41 
intervention has been reported to reduce progression to diabetes by 35% and metformin by 40% 32.  42 
Breast feeding for > 10 months has been reported to decrease the risk of diabetes at two years 43 
postpartum by 57% in women with a history of GDM 33.  44 
The HAPO FUS clearly confirms that pregnancy is a window of opportunity to identify mothers and 45 
offspring with substantial future health risks.  Given the continuous association between glucose 46 
exposure and both immediate pregnancy complications and later cardiometabolic risks, there is no 47 
“perfect” set of glucose thresholds, during or following pregnancy, that will identify most women and 48 
children at risk. Questions both of individual clinical and broader public health risks and benefits, 49 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 6 
opportunity costs and health economics must be considered when deciding on diagnostic processes 1 
and cut-offs. 2 
 3 
Randomized trials – health benefits and health economic benefits 4 
There is clear evidence from the landmark Crowther 34 and Landon 35 trials that GDM treatment 5 
improves immediate pregnancy outcomes related to excess fetal growth (LGA in both studies, 6 
neonatal fat mass also measured in the Landon study) and hypertensive disorders of pregnancy by 7 
40 -  50%.   Of note, the sole inclusion criterion for the Crowther study was a 2 hour OGTT glucose ≥ 8 
140 mg / dL, representing less severe hyperglycemia than the IADPSG GDM definition.   Direct health 9 
economic analysis of the Crowther study reported that GDM treatment was highly cost effective, at 10 
AUD60,506 per perinatal death prevented and AUD2988 per quality adjusted life year (QALY) gained 11 
36
.  A US based analysis using data from the Landon study also suggested an acceptable cost / 12 
benefit ratio of USD20412 / QALY gained 37.  More indirect “modelling” studies provide more varied 13 
results 38-40, but all conclude that treatment is highly cost effective if interventions to reduce future 14 
maternal diabetes risk are included.   15 
One step vs. two step testing and one vs. two abnormal values on oral glucose tolerance 16 
testing 17 
Table 2 provides a comparison of current diagnostic thresholds for GDM.  The 2018  guidelines from 18 
the American College of Obstetricians and Gynecologists 41 remain highly ambivalent, stating only 19 
that “practitioners and institutions should select a single set of diagnostic criteria”.  This inconclusive 20 
approach tacitly endorses even the largely discredited National Diabetes Data Group (NDDG) 21 
thresholds for GDM diagnosis 42-44, contrary to current recommendations from the American Diabetes 22 
Association 45. Although the substantially higher NDDG glucose cut – offs limit the number of GDM 23 
diagnoses, they have the capacity to increase overall healthcare costs by virtue of increased maternal 24 
and neonatal complications 46.    ACOG continues to endorse “two step” testing (glucose 1 hour post 25 
non-fasting 50 gram glucose load, followed by OGTT if positive) as its preferred option, without clearly 26 
stating what glucose result should prompt a full OGTT.  We note that this approach systematically 27 
does not detect around 25% of women with GDM 47, delays diagnosis (and thus therapy) and leads to 28 
a risk of process errors, in particular failure to follow up on a “positive screen” 48, 49.     29 
Additionally, we would note that the lower GDM diagnosis rates with Carpenter - Coustan or NDDG 30 
criteria are due largely to the requirement for two values > threshold on the diagnostic OGTT for a 31 
confirmed GDM diagnosis. All other dysglycemic states (diabetes, IFG, IGT) are diagnosed based on 32 
a single abnormal value.  Surely, pregnancy is one situation where any degree of dysglycaemia with 33 
its multi-generational consequences should be taken seriously!  The “two abnormal values” caveat is 34 
essentially an historical quirk, empirically proposed post hoc by O’Sullivan in Mahan in 1964 with the 35 
cryptic comment: “it was considered expedient” following their  early cohort studies 3.  Indeed, in  36 
1961, O’Sullivan reported GDM diagnoses generally requiring three abnormal OGTT values 50.  The 37 
continued insistence two abnormal values for diagnosis serves to reduce GDM frequency, but not in 38 
any logical fashion 51-53. It is almost thirty years since a randomized trial by Langer and colleagues 39 
demonstrated that treatment of women with one abnormal value on OGTT improved pregnancy 40 
outcomes 54.  Postpartum follow up studies also clearly demonstrate that even women with a positive 41 
glucose screen and a negative OGTT, and certainly women with a single abnormal OGTT value, have 42 
worsening β cell function and dysglycemia within the first year postpartum 55.   43 
Do we need a new, “definitive” randomized controlled trial? 44 
A further argument advanced by critics is that the IADPSG cut-offs values have not been formally 45 
used in any randomized trial 15.  We acknowledge this issue, but note that the Crowther 34 and Landon 46 
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35
 trials included women whose OGTT results, age and BMI substantially overlap with women who 1 
would be diagnosed under the IADPSG criteria 56.  Given the known continuous relationship between 2 
glucose exposure and risk, it seems most unlikely that a new study specifically using IADPSG cut – 3 
offs would deliver a different result.  Furthermore, with definite clinical benefits including reduction of 4 
excess fetal growth and its consequences and reduction in hypertensive disorders of pregnancy now 5 
well established on systematic review 57 any further study would pose ethnical issues. 6 
Implementation and pre / post cohort studies 7 
Issues related to implementation of the IADPSG GDM diagnostic strategy have recently been 8 
reviewed by Brown and Wyckoff 58 , who note that women diagnosed post hoc as GDM by IADPSG 9 
criteria have worse outcomes that those with normal glucose tolerance, “indicating a likely opportunity 10 
to improve outcomes with treatment.”  Cohort studies conducted on a pre / post basis after a “whole of 11 
system” change from two step Carpenter - Coustan testing to one step IADPSG testing have shown 12 
variable results.  Duran et al 59 reported a threefold increased frequency of GDM diagnoses (from 13 
10.6 to 35.5%) with this change, but noted that the increased costs of treatment were more than offset 14 
by a reduction in peripartum costs, principally related to reduced rates of cesarean delivery and 15 
newborn intensive care unit admission.  Of note, the percentage of women requiring insulin therapy 16 
under the IADPSG criteria was constant at around 20%, suggesting that the change in approach did 17 
not result in the detection of trivial or clinically insignificant hyperglycemia in pregnancy.  18 
By contrast, a US based cohort study from Kaiser Permanente California 60, also evaluating a change 19 
from Carpenter - Coustan testing to IADPSG testing, reported an increase in GDM from 17 to 27% 20 
without any change in pregnancy outcomes.  However, in addition to the change in standard GDM 21 
screening, this group also introduced early glycosylated hemoglobin (HbA1c) testing into routine 22 
clinical practice.  The majority of the increase in GDM prevalence appeared due to early HbA1c 23 
testing, with a consequent increase in what they termed “pre-diabetes” from 4 to 11%.  This clearly 24 
suggests a high rate of pre-pregnancy impaired glucose metabolism in their population. Such women 25 
are known to be at higher risk and may benefit less from routine treatment 61.  Further, clinical practice 26 
in this center clearly changed over the course of the study, with glyburide replacing insulin as the 27 
predominant mode of pharmacotherapy.  This may also have contributed to worsening of outcomes 62, 28 
63
.  A more recent report from Kaiser Permanente Washington State 64 also reported an increase in 29 
GDM from 6.9 to 11.4% after a similar change in diagnostic protocol, without improved overall 30 
pregnancy outcomes.  Of note, their “post IADPSG” rate of GDM diagnosis was still substantially 31 
lower than any US based center in the HAPO study 16, suggesting a population at low overall risk.  32 
Again, this study introduced early HbA1c testing at the same time, but failed to separately document 33 
the rate of abnormal early testing.  34 
Saccone et al have recently published a systematic review of all randomized studies comparing the 35 
“two step” and “one step” approaches 65.  They conclude that overall perinatal outcomes are improved 36 
with the IADPSG approach, with evidence for reduction in LGA, NICU admission and neonatal 37 
hypoglycemia.   38 
Maternal GDM treatment, breast feeding and offspring risks 39 
Offspring exposed to maternal hyperglycemia in pregnancy, independent of maternal obesity, are at a 40 
significantly heightened risk of early onset obesity, type 2 diabetes and cardio-metabolic disorders as 41 
a consequence of intrauterine developmental programing 13, 66, 67.  A report from Germany including 42 
adjustment for maternal BMI and other potential confounders comparing GDM and non GDM offspring 43 
yielded an OR of 1.81 (95% CI 1.23-2.65) for childhood overweight and 2.80 (95% CI 1.58-4.99) for, 44 
respectively.  Similar results were obtained for the risk of childhood abdominal adiposity (OR 1.64, 45 
95% CI 1.16-2.33) by maternal gestational diabetes.  A study from Israel has also reported an 46 
association between diet treated GDM and offspring cardiovascular morbidity:  (RR 1.6, 95% CI 1.2–47 
2.2) 68.  The effects of maternal GDM treatment on offspring risk of obesity and impaired glucose 48 
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metabolism are much less clear.  Follow up from the Crowther 69 and Landon 70 randomized trials has 1 
failed to demonstrate any clear overall benefit of maternal GDM treatment for the offspring, although 2 
the Landon study suggested some possible improvement in metabolic status for girls whose mothers 3 
were treated for GDM.  Recent US based evidence from Gunderson et al shows that breast feeding 4 
can attenuate some of these risks, with weight for length Z score reduced by 0.36 to 0.45 SD units at 5 
12 months of age in GDM offspring who were intensively breast fed 67, but definitive evidence of 6 
longer term benefit is lacking. 7 
GDM as a global health issue 8 
Thus far, our commentary has focused primarily on GDM as it affects US – based clinical practice.  9 
However, the issues are even more pressing on a global scale 71, 72.  Hyperglycemia in pregnancy is  10 
estimated to have affected 21.4 million live births in 2013, with over 90% of cases occurring in low -11 
middle income countries which lack sufficient resources to provide optimal care 71. Moreover, in 12 
populous low and middle income countries (South Asia 37 million and China 18 million pregnancies 13 
annually) with limited resources, the recommendation for a two-step approach for diagnosis is 14 
impractical and will result in only a small fraction of the target population being tested.  The 15 
International Federation of Gynecology and Obstetrics (FIGO) has addressed this pressing health 16 
issue by producing and promoting pragmatic worldwide guidelines for diagnosis and treatment of 17 
hyperglycemia in pregnancy 8.  In collaboration with the International Diabetes Federation (IDF), FIGO 18 
has produced firm declarations regarding the importance of hyperglycemia in pregnancy 73, 74.  This is 19 
the first time that such a broad global consensus has been achieved.    These declarations have been 20 
endorsed by governments in many areas of the world.  A global consensus document was signed at 21 
the FIGO 2018 world congress.  FIGO has also formed  a “Pregnancy and prevention of early non – 22 
communicable disease” (NCD) subcommittee to effectively address the prevention of NCDs by 23 
highlighting the importance maternal nutrition, obesity, hyperglycemia and hypertension and pre term 24 
delivery as major antecedents to and markers of later NCD risk 75. 25 
In conclusion, we consider that the HAPO FUS has provided important evidence to demonstrate that 26 
identification of hyperglycemia in pregnancy may identify  a large number of women may benefit from 27 
interdisciplinary medical intervention in pregnancy and post-partum follow up.  Without appropriate 28 
diagnostic strategies and careful follow up, this opportunity will be lost and the current epidemics of 29 
obesity and diabetes will continue unchecked. 30 
What is now needed is not further contemplation but rather action, impeded in the USA by denial of 31 
what we consider compelling evidence that IADPSG GDM, although it is somewhat less severe than 32 
the hyperglycemia identified by older criteria, merits detection and treatment.  We strongly urge our 33 
US based colleagues, both individually and through major groups such as ACOG and the Society for 34 
Maternal - Fetal Medicine (SMFM), to realistically address the challenges posed by hyperglycemia in 35 
pregnancy, to promote women’s health by taking a “whole of life” approach to this and other maternal 36 
risk factors and to energetically support efforts to reduce the personal, economic and societal harms 37 
caused by this global epidemic.  38 
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Table 1.  Perinatal and long-term outcomes in untreated women subsequently classified as 1 
gestational diabetes mellitus (GDM) or non GDM by International Association of Diabetes in 2 
Pregnancy Study Groups criteria in the Hyperglycemia and Adverse Pregnancy Outcome study 3 
participants and their offspring 4 
 5 
Outcome IADPSG GDM (%) Non GDM (%) 
Perinatal outcomes 56 (from HAPO 
study) 
  
   
Pre-eclampsia** 9.1 4.5 
Preterm delivery (< 37 weeks)** 9.4 6.4 
Primary cesarean delivery** 24.4 16.8 
Shoulder dystocia / birth injury* 1.8 1.3 
Birthweight > 90th centile** 16.2 8.3 
Newborn % body fat > 90th centile** 16.6 8.5 
Cord c peptide > 90th centile** 17.5 6.7 
Clinical neonatal hypoglycemia** 2.7 1.9 
Admission to newborn intensive care* 9.1 7.8 
   
Long term outcomes 13 (from HAPO 
Follow Up Study) 
  
   
Maternal diabetes** 10.7 1.6 
Maternal prediabetes** 41.5 18.4 
Offspring overweight or obesity** 39.5 28.6 
Offspring obesity** 19.1 9.9 
Offspring body fat > 85th centile** 21.7 13.9 
 6 
Perinatal outcomes relate to the 23316 women and their singleton offspring in the blinded 7 
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) cohort.  Long-term outcomes relate to 8 
4697 women and 4832 offspring from the HAPO follow up cohort, examined at a mean of 11.4 years 9 
post birth.  International Association of Diabetes in Pregnancy Study Groups (IADPSG) gestational 10 
diabetes mellitus (GDM) was defined as one or more values greater than or equal to the following on 11 
the 75 gram OGTT (mg/dL): Fasting 92; 1 hour 180; 2 hour 153.   ** = p < 0.001; * p < 0.01 comparing 12 
IADPSG GDM and non GDM groups. 13 
 14 
 15 
16 
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Table 2.  Criteria for gestational diabetes using thresholds recommended by Carpenter Coustan, 1 
National Diabetes Data Group and International Association of Diabetes in Pregnancy Study Groups 2 
 3 
 4 
Criteria Fasting glucose 
(mg/dL) 
1 hour glucose 
(mg/dL) 
2 hour glucose 
(mg/dL) 
3 hour glucose 
(mg/dL) 
Carpenter 
Coustan 
95 180 155 140 
National Diabetes 
Data Group 
105 190 165 145 
IADPSG 92 180 153 N/C 
 5 
Comparison of diagnostic venous plasma glucose cutoff values for gestational diabetes according to 6 
various criteria using the oral glucose tolerance test (OGTT).  Carpenter Coustan 14 and National 7 
Diabetes Data group 41 criteria generally relate to a 100 gram OGTT, include an additional glucose 8 
measurement at 3 hours post load and require two values ≥ threshold for diagnosis.  International 9 
Association of Diabetes in Pregnancy Study Group (IADPSG) criteria 2 relate to at 75 gram OGTT and 10 
require only one value > threshold for diagnosis. N/C  = Not Considered. 11 
 12 
  13 
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Legend for Figure 1 1 
Frequency of primary outcomes in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) 2 
Study, classified by  fasting venous plasma glucose categories (ranges in mg/dL).  LGA (black circles) 3 
– large for gestational age (birthweight > 90th centile); Primary C section (red squares)  - primary 4 
cesarean section delivery; NN hypo (green triangles)  – clinical neonatal hypoglycemia; NN 5 
hyperinsulinemia –  (blue diamonds) cord c peptide > 90th centile 6 
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Hyperglycemia	and	Pregnancy	
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Hyperglycemia	in	Pregnancy	is	Grossly	Neglected
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Hyperglycemia	in	pregnancy	is	a	reliable	marker	of	future	
• Type	2	diabetes;	relative	risk	(RR)	7.43	(95%	CI	4.79–
11.51).	[Bellamy	L	et	al	Lancet	2009;373:1773-9.]	
• Cardio	metabolic	disorders	(RR	1.66,	95%	CI	1.30-2.13)	
[Retnakaran R,	Shah	BR.	CMAJ	2009;181:371-6;	Kessous R	
et	al.	Heart	2013;	99:	1118-21]
• Renal	disease	(OR)		2.3,	95%	CI	1.4-3.7).	[Beharier O	et	al.	
J	Clin Endocrinol Metab 2015;100:1412-6.]		
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In	women	with	prior	GDM	post-partum	intervention	
reduces	progression	to	diabetes	
• Lifestyle	by	35%	and	metformin	by	40%.	[Aroda VR	et	
al.	J	Clin Endocrinol Metab 2015;100:1646-53.]	
• Breast	feeding	for	>	10	months	by	57%		within	two	
years	[Gunderson	EP.	et	al.	Annals	of	internal	
medicine	2015;163:889-98.27.]	
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If	US	women	of	reproductive	age	were	routinely	tested	prior	to	
pregnancy,	over	30%	would	be	found	to	have	prediabetes	or	
diabetes	
National	Health	and	Nutrition	Examination	(NHANES)	surveys	
demonstrate	that	among	US	adults	age	20	– 44	years
• 4.5%	have	overt	diabetes	[.	JAMA	2015;314:1021-9.]
• 29.3%	have	prediabetes	(HbA1c	5.7	– 6.4	and	/	or	fasting	glucose	
100	– 126	mg	/dL	and	/	or	2	hour	OGTT	glucose	140	– 199	mg	/	
dL)	[Menke A	et	al.	Ann	Epidemiol 2018.15.]		
• Even	at	age	12	– 19	years,	diabetes	affects	0.6%	and	prediabetes	
13.2%	of	US	females	[Menke A	et	al	JAMA	2016;316:344-5.]			
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In	utero	exposure	to	maternal	hyperglycemia,	independent	
of	maternal	obesity,	significantly	increases	risk	of	early	onset	
obesity,	type	2	diabetes	and	cardio-metabolic	disorders
Lowe	WL	et	al.	JAMA	2018;	320:1005-16;	
Nehring I	et	al.	Diabet Med	2013;	30:	1449-56;		
Dablea D	et	al.	Diabetes	Care	2008;31:1422-6.
Significant	association	between	insulin	as	well	as	diet	treated	
GDM	and	offspring	cardiovascular	morbidity:		(RR	1.6,	95%	CI	
1.2–2.2)	
Leybovitz-Haleluya N	et.al	Acta	Diabetol.	2018	Jun	23.	doi:	10.1007/s00592-018-
1176-1
The	effects	of	maternal	GDM	treatment	on	offspring	risk	of	
obesity	and	impaired	glucose	metabolism	are	less	clear
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Immediate	and	Long	Term	Outcomes
IADPSG	GDM
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HAPO	Study	and	HAPO	Follow	Up	Study	Outcomes	by	IADPSG	GDM	category
IADPSG	GDM	(%) Non	GDM	(%) 
Pregnancy	Outcomes Long	Term	Outcomes
GDM	vs	non	GDM	comparisons:	*	p	<	0.01;	**	P	<	0.001
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Treatment	of	GDM	Reduces	Adverse	
Outcomes	– Crowther	Study	*
OUTCOME ROUTINE	CARE					(N	=	510)
INTERVENTION					
(N	=	490) P
Birth	Weight 3482	+ 660 3335	+ 551 <	.001
LGA 22% 13% <	.001
Macrosomia 21% 10% <	.001
Preeclampsia 18% 12% 0.02
SGA 7% 7% ns
*Crowther CA, et al. NEJM 352:2477-86, 2005
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Treatment	of	GDM	Reduces	Adverse	
Outcomes	– Landon	Study*
Outcome
NICHD RCT
P
Not treated Treated
BW >90th
percentile 14.5 7.1 <0.001
C-peptide >95th
percentile 22.8 17.7 0.07
NICU admission 11.6 9.0 0.19
Shoulder 
Dystocia 4.0 1.5 0.02
Preeclampsia 5.5 2.5 0.02
*Landon MB et al. NEJM 361:1339-48, 2009
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GDM	Clinical	and	Cost	Effectiveness	Model
Societal Perspective
